JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Simulations Plus Inc

Fermé

SecteurSoins de santé

14.52 2.11

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.42

Max

14.6

Chiffres clés

By Trading Economics

Revenu

3.9M

4.5M

Ventes

5.9M

24M

BPA

0.35

Rendement du dividende

0.48

Marge bénéficiaire

18.669

Employés

212

EBITDA

4.9M

7.2M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.89% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.48%

2.24%

Prochains Résultats

13 juil. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

51M

302M

Ouverture précédente

12.41

Clôture précédente

14.52

Sentiment de l'Actualité

By Acuity

26%

74%

88 / 348 Classement par Healthcare

Simulations Plus Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 19:19 UTC

Acquisitions, Fusions, Rachats

Intertek Group Rejects EQT's Revised Offer

24 avr. 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Scoring the Cook Era -- Barrons.com

24 avr. 2026, 20:51 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 avr. 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:09 UTC

Résultats

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 avr. 2026, 19:48 UTC

Market Talk
Principaux Événements d'Actualité

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 avr. 2026, 19:22 UTC

Résultats

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 avr. 2026, 19:06 UTC

Résultats

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 avr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 avr. 2026, 18:30 UTC

Acquisitions, Fusions, Rachats

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 avr. 2026, 18:28 UTC

Acquisitions, Fusions, Rachats

Intertek Rejects Revised EQT Offer

24 avr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 avr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 avr. 2026, 17:42 UTC

Résultats

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 avr. 2026, 17:28 UTC

Résultats

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 avr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 avr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 avr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 avr. 2026, 17:09 UTC

Market Talk
Résultats

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 avr. 2026, 17:09 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 17:06 UTC

Résultats
Acquisitions, Fusions, Rachats

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 avr. 2026, 16:51 UTC

Résultats
Acquisitions, Fusions, Rachats

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

24 avr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparaison

Variation de prix

Simulations Plus Inc prévision

Objectif de Prix

By TipRanks

9.89% hausse

Prévisions sur 12 Mois

Moyen 16 USD  9.89%

Haut 16 USD

Bas 16 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

88 / 348Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat